Скачать с ютуб Treatment of High-Risk NMIBC: What's New? w/ Dr. Ashish Kamat | Urology Podcast Ep. 177 в хорошем качестве

Treatment of High-Risk NMIBC: What's New? w/ Dr. Ashish Kamat | Urology Podcast Ep. 177

In this episode of the BackTable Urology Podcast, Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena. --- CHECK OUT OUR SPONSOR Siemens Healthineers Theranostics https://www.siemens-healthineers.com/... --- SYNPOSIS Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine. --- TIMESTAMPS 00:00 - Introduction 03:56 - Initial Diagnosis and Workup 12:22 - High-Grade Bladder Cancer 22:37 - BCG and Alternative Treatments 31:30 - BCG Unresponsive Disease 36:56 - Novel Intravesical and Systemic Therapies 46:45 - Future Directions --- RESOURCES Related BackTable episodes: https://www.backtable.com/shows/urolo... https://www.backtable.com/shows/urolo... https://www.backtable.com/shows/urolo... --- The BackTable Urology Podcast is a resource for practicing urologists to learn tips, techniques, and practical advice from their peers in the field. Listen on BackTable.com/Urology or on the streaming platform of your choice. Get notified when new episodes drop! Subscribe to the BackTable Urology Podcast on your go-to podcast platform, and follow us on your social media platform of choice for regular updates. ► https://www.backtable.com/shows/urolo... #nmibc #bladdercancer #urologiconcology #URO177